Publications of M. Adham Salkeni, MD

Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.
Farrugia MK, Sharma SB, Lin CC, McLaughlin SL, Vanderbilt DB, Ammer AG, Salkeni MA, Stoilov P, Agazie YM, Creighton CJ, Ruppert JM.
Cell Death Dis. 2015;6:e1699

PMC4385942.

Optimal management of sentinel lymph node positive biopsy patients in early breast cancer.
Jacobson GM, Partin JF, Salkeni MA.
Ann Transl Med. 2015;3(7):87

PMC4430736.

microRNAs-206 and -21 cooperate to promote RAS-ERK signaling by suppressing the translation of RASA1 and SPRED1.
Sharma SB, Lin CC, Farrugia MK, McLaughlin SL, Ellis EJ, Brundage KM, Salkeni MA, Ruppert JM.
Mol Cell Biol. 2014;34(22):4143-4164.

PMC4248710.

Bevacizumab and Glioblastoma Multiforme: A thrombosis and bleeding dilemma (A case report and a brief review of the literature).
Patel D, Salkeni MA, Chaudhary R.
Am J Ther. 2013; [Epub ahead of print]


Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients.
Salkeni MA, Zarzour A, Ansay TY, McPherson CM, Warnick RE, Rixe O, Bahassi EM.
J Neurooncol. 2013;115(1):27-35.


Lipopolysaccharide impairs blood-brain barrier P-glycoprotein function in mice through prostaglandin- and nitric oxide-independent pathways.
Salkeni MA, Lynch JL, Otamis-Price T, Banks WA.
J Neuroimmune Pharmacol. 2009;4(2):276-282.

PMC2802264.